Aimmune therapeutics, inc. (AIMT)
CashFlow / Yearly
Dec'19Dec'18Dec'17Dec'16Dec'15
Cash flows from operating activities:
Net loss

-248,497

-210,752

-131,325

-80,824

-35,816

Adjustments to reconcile net loss to net cash used in operating activities
Depreciation expense

4,100

1,600

1,000

534

115

Stock-based compensation expense

32,929

32,732

16,719

12,641

6,157

Non-cash interest expense

4,626

-

-

-

-

Amortization of premium on investment securities

1,631

886

-511

-919

-324

Changes in operating assets and liabilities:
Prepaid expenses and other assets

-3,888

1,995

1,435

-3,967

9,698

Accounts payable

6,200

2,688

2,315

-994

1,072

Accrued liabilities

2,039

7,412

11,557

6,803

1,859

Other liabilities

952

75

1,087

340

297

Net cash used in operating activities

-195,400

-169,128

-99,605

-56,614

-35,690

Purchase of property and equipment

8,047

9,420

6,425

7,665

1,708

Purchase of investments

166,321

261,293

129,534

197,178

152,811

Maturities of investments

286,267

174,703

178,521

160,947

29,250

Net cash provided by (used in) investing activities

111,899

-96,010

42,562

-43,896

-125,229

Cash flows from financing activities:
Borrowings under debt agreement

40,000

-

-

-

-

Debt issuance costs

3,856

-

-

-

-

Change in restricted cash

-

-

-

-

-40

Proceeds from underwritten public offering, net of offering costs

-

288,435

6,520

145,000

168,119

Net cash proceeds from exercise of stock options

20,406

10,727

-

2,843

303

Tax withholdings related to net share settlements of restricted stock units

672

-

-

-

-

Net cash provided by financing activities

55,878

299,162

6,520

147,843

235,327

Net increase (decrease) in cash and cash equivalents

-27,631

34,024

-50,523

47,333

74,408

Supplemental disclosure of non-cash investing and financing activities:
Property and equipment purchases included in accounts payable and accrued liabilities

1,048

1,301

1,355

558

-

Capital expenditures and interest funded through long term lease obligation

-

-

-

-

710

Supplemental cash flow disclosures:
Cash paid for taxes

-

148

39

-

-